Teva Pharmaceutical Industries
Market Cap
US$8.6b
Last Updated
2019/07/19 23:47 UTC
Data Sources
Company Financials +
Executive Summary
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.
Snowflake
Fundamentals
Fair value with moderate growth potential.
Risks
- Teva Pharmaceutical Industries has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has Teva Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-14.5%
NYSE:TEVA
-0.9%
US Pharmaceuticals
-1.2%
US Market
1 Year Return
-65.5%
NYSE:TEVA
3.7%
US Pharmaceuticals
3.4%
US Market
TEVA underperformed the Pharmaceuticals industry which returned 4.7% over the past year.
TEVA underperformed the Market in United States of America which returned 3.9% over the past year.
Share holder returns
| TEVA | Industry | Market | |
|---|---|---|---|
| 7 Day | -14.5% | -0.9% | -1.2% |
| 30 Day | -3.3% | -4.0% | 1.2% |
| 90 Day | -44.9% | 0.8% | 1.7% |
| 1 Year | -65.5%-65.5% | 6.2%3.7% | 5.7%3.4% |
| 3 Year | -84.9%-85.5% | 7.8%0.2% | 45.0%35.5% |
| 5 Year | -84.2%-85.5% | 25.6%12.1% | 59.3%41.6% |
Price Volatility Vs. Market
How volatile is Teva Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way1 month ago | Simply Wall St
What Kind Of Shareholders Own Teva Pharmaceutical Industries Limited (NYSE:TEVA)?3 months ago | Simply Wall St
Those Who Purchased Teva Pharmaceutical Industries (NYSE:TEVA) Shares Three Years Ago Have A 71% Loss To Show For ItValuation
Is Teva Pharmaceutical Industries undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Teva Pharmaceutical Industries's share price is below the future cash flow value, and at a moderate discount (> 20%).
Teva Pharmaceutical Industries's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Teva Pharmaceutical Industries is loss making, we can't compare its value to the US Pharmaceuticals industry average.
Teva Pharmaceutical Industries is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Teva Pharmaceutical Industries, we can't assess if its growth is good value.
Price Based on Value of Assets
Teva Pharmaceutical Industries is good value based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is Teva Pharmaceutical Industries expected to perform in the next 1 to 3 years based on estimates from 23 analysts?
64.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Teva Pharmaceutical Industries's revenue is expected to grow by 0.7% yearly, however this is not considered high growth (20% yearly).
Teva Pharmaceutical Industries's earnings are expected to grow significantly at over 20% yearly.
Teva Pharmaceutical Industries's revenue growth is positive but not above the United States of America market average.
Teva Pharmaceutical Industries's earnings growth is expected to exceed the United States of America market average.
Teva Pharmaceutical Industries's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Teva Pharmaceutical Industries is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Teva Pharmaceutical Industries performed over the past 5 years?
-64.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Teva Pharmaceutical Industries does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Teva Pharmaceutical Industries's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Teva Pharmaceutical Industries's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Teva Pharmaceutical Industries has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Teva Pharmaceutical Industries has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Teva Pharmaceutical Industries improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Teva Pharmaceutical Industries's financial position?
Financial Position Analysis
Teva Pharmaceutical Industries's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Teva Pharmaceutical Industries's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Teva Pharmaceutical Industries's level of debt (180.9%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (51.2% vs 180.9% today).
Balance Sheet
Low level of unsold assets.
Debt is not covered by short term assets, assets are 0.5x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Whilst loss making Teva Pharmaceutical Industries has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
Whilst loss making Teva Pharmaceutical Industries has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 41.6% per year.
Next Steps
Dividend
What is Teva Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Teva Pharmaceutical Industries's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Teva Pharmaceutical Industries's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Teva Pharmaceutical Industries has not reported any payouts.
Unable to verify if Teva Pharmaceutical Industries's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Teva Pharmaceutical Industries has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Teva Pharmaceutical Industries's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Teva Pharmaceutical Industries's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
Kåre Schultz (58yo)
1.7yrs
Tenure
US$32,469,875
Compensation
Mr. Kåre Schultz has been the Chief Executive Officer, President and Director of Teva Pharmaceutical Industries Limited since November 1, 2017. Mr. Schultz is a seasoned veteran in the healthcare industry ...
CEO Compensation Analysis
Kåre's remuneration is higher than average for companies of similar size in United States of America.
Kåre's compensation has increased whilst company is loss making.
Management Age and Tenure
3.4yrs
Average Tenure
53yo
Average Age
The tenure for the Teva Pharmaceutical Industries management team is about average.
Board Age and Tenure
2.2yrs
Average Tenure
63yo
Average Age
The average tenure for the Teva Pharmaceutical Industries board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month individual insider trading information.
Ownership Breakdown
Management Team
Mike McClellan (48yo)
Executive VP & CFO
- Tenure: 2.0yrs
- Compensation: $4.95m
Kevin Mannix
Senior Vice President of Investor Relations
Hafrun Fridriksdottir (57yo)
Executive Vice President of Global R&D
- Tenure: 2.4yrs
- Compensation: $5.98m
Kåre Schultz (58yo)
President
- Tenure: 1.7yrs
- Compensation: $32.47m
Deborah Griffin
Senior VP & Chief Accounting Officer
David Stark (50yo)
Executive VP & Chief Legal Officer
- Tenure: 2.7yrs
Mark Sabag (48yo)
Executive Vice President of Global Human Resources
- Tenure: 5.9yrs
- Compensation: $5.25m
Lori Queisser
Senior VP & Global Compliance Officer
- Tenure: 4.1yrs
Iris Beck-Codner (53yo)
Executive Vice President of Global Brand & Communications
- Tenure: 5.0yrs
Carlo de Notaristefani (61yo)
Executive Vice President of Global Operations
- Tenure: 6.9yrs
- Compensation: $7.24m
Board Members
Roberto Mignone (47yo)
Independent Director
- Tenure: 2.0yrs
- Compensation: $241.43k
Kåre Schultz (58yo)
President
- Tenure: 1.7yrs
- Compensation: $32.47m
Murray Goldberg (74yo)
Independent Director
- Tenure: 2.0yrs
- Compensation: $245.71k
Perry Nisen (63yo)
Independent Director
- Tenure: 2.0yrs
- Compensation: $211.71k
Chemi Peres (60yo)
Independent Director
- Tenure: 2.0yrs
- Compensation: $235.53k
Jerry Lieberman (72yo)
Director
- Tenure: 3.8yrs
- Compensation: $250.72k
Amir Elstein (63yo)
Independent Director
- Tenure: 10.5yrs
- Compensation: $246.32k
Jean-Michel Halfon (67yo)
Independent Director
- Tenure: 5.1yrs
- Compensation: $232.68k
Rose Crane (59yo)
Independent Director
- Tenure: 3.8yrs
- Compensation: $235.00k
Sol Barer (72yo)
Chairman of the Board
- Tenure: 2.4yrs
- Compensation: $378.00k
Company Information
Teva Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Teva Pharmaceutical Industries Limited
- Ticker: TEVA
- Exchange: NYSE
- Founded: 1901
- Industry: pharmaceuticals
- Sector: pharmaceuticals & biotech
- Market Cap: US$8.641b
- Shares outstanding: 1.09b
- Website: Click here
Number of Employees
Location
- Teva Pharmaceutical Industries Limited
- 5 Basel Street
- Petach Tikva
- 4951033
- Israel
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TEVA | NYSE (New York Stock Exchange) | Yes | ADR-EACH CNV INTO 1 ORD ILS0.10 | US | USD | Feb 1982 |
| TEV | DB (Deutsche Boerse AG) | Yes | ADR-EACH CNV INTO 1 ORD ILS0.10 | DE | EUR | Feb 1982 |
| TEVA N | BMV (Bolsa Mexicana de Valores) | Yes | ADR-EACH CNV INTO 1 ORD ILS0.10 | MX | MXN | Feb 1982 |
| TEVA | SWX (SIX Swiss Exchange) | Yes | ADR-EACH CNV INTO 1 ORD ILS0.10 | CH | CHF | Feb 1982 |
| 0LER | LSE (London Stock Exchange) | Yes | ADR-EACH CNV INTO 1 ORD ILS0.10 | GB | USD | Feb 1982 |
| TEVA | WBAG (Wiener Boerse AG) | Yes | ADR-EACH CNV INTO 1 ORD ILS0.10 | AT | EUR | Feb 1982 |
| TEVJ.F | OTCPK (Pink Sheets LLC) | Ordinary Shares | US | USD | Jun 1994 | |
| TEVA | TASE (The Tel-Aviv Stock Exchange) | Ordinary Shares | IL | ILS | Jun 1994 |
Biography
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through tw ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/07/19 23:47 |
| End of Day Share Price | 2019/07/19 00:00 |
| Earnings | 2019/03/31 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.